Document is current
Any future updates will be listed below
-
Authors
Prescott, Maximo R. https://orcid.org/0000-0003-1879-1835
Chentsova, Victoria
Delgado, Jorge
Dung, Devin
Shoptaw, Steven
Aarons, Gregory A.
Moore, David J.
Grelotti, David
Montoya, Jessica
-
Funding
Funding for this research was provided by:
Intramural Research Program, National Institute on Drug Abuse (5T32DA031098)
Intramural Research Program, National Institute on Drug Abuse (5T32DA031098)
Intramural Research Program, National Institute on Drug Abuse (5K23DA051324)
National Institute of Mental Health (P30MH062512)
- License Information
-
More Information
Article History
Accepted: 19 March 2026
First Online: 13 May 2026
Declarations
:
: Dr. Steve Shoptaw reports receiving clinical supplies for his research over the past three years from the following non-exempt companies: Alkermes, Inc.; Gilead Sciences, Inc.; and Indivior, Inc. He provides consultation services to Clear Scientific, Inc. to support the development of a medication for methamphetamine use disorder. He also provides consultation services to Eli Lilly and Company as part of their Data and Safety Monitoring Board (DSMB) system. The other authors of this manuscript have no competing interests to declare.
